10-QPeriod: Q1 FY2025

STRYKER CORP Quarterly Report for Q1 Ended Mar 31, 2025

Filed May 2, 2025For Securities:SYK

Summary

Stryker Corporation (SYK) reported its first-quarter 2025 results, showcasing robust top-line growth driven by strategic acquisitions and organic expansion. Net sales increased by 11.9% year-over-year to $5.87 billion, with constant currency growth of 12.8%. This growth was propelled by a 13.4% increase in the MedSurg and Neurotechnology segment and a 9.7% rise in the Orthopaedics segment. The company's profitability faced pressure from increased selling, general, and administrative expenses, largely due to acquisition-related costs, including a significant charge for Inari employee stock awards. As a result, net earnings decreased by 17.0% to $654 million, and diluted EPS fell to $1.69 from $2.05 in the prior year. However, adjusted EBITDA margin showed a healthier trend, indicating underlying operational strength. Financially, Stryker bolstered its liquidity through significant debt issuances, raising $2.98 billion in long-term debt. The company ended the quarter with a strong cash position, though it was reduced by substantial investing activities, primarily the Inari acquisition. The strategic acquisition of Inari, a leader in minimally invasive products for venous thromboembolism, is expected to enhance Stryker's Vascular business and drive future growth.

Financial Highlights

52 data points
Beta

Revenue

$5.87B

63.8% Gross Margin

Net Income

$654.00M

11.1% Net Margin

EPS (Diluted)

$1.69

Total Assets

$46.01B

Cash & Equivalents

$2.32B

Free Cash Flow

$127.00M

Financial Statements
Beta
Revenue$5.87B
Cost of Revenue$2.12B
Gross Profit$3.74B
R&D Expenses$405.00M
SG&A Expenses$2.30B
Operating Expenses$2.91B
Operating Income$837.00M
Interest Expense$132.00M
Net Income$654.00M
EPS (Basic)$1.71
EPS (Diluted)$1.69
Shares Outstanding (Basic)381.70M
Shares Outstanding (Diluted)386.40M

Key Highlights

  • 1Net sales grew 11.9% to $5.87 billion, driven by 13.4% in MedSurg/Neurotechnology and 9.7% in Orthopaedics.
  • 2Acquisition of Inari Medical for $4.75 billion significantly boosted the Vascular business and contributed to overall sales growth.
  • 3Net earnings declined 17.0% to $654 million ($1.69/share) due to increased SG&A expenses, particularly acquisition-related costs.
  • 4Selling, General, and Administrative (SG&A) expenses rose 25.2% primarily due to a $139 million charge for Inari employee stock awards and other integration costs.
  • 5The company raised $2.98 billion in new long-term debt, enhancing its liquidity position.
  • 6Stryker is divesting its US Spinal Implants business, completing the sale in April 2025.
  • 7Operating income margin decreased to 14.3% from 18.5% in the prior year, impacted by higher operating expenses.

Frequently Asked Questions

Stryker's top-line growth was driven by a combination of organic growth across its MedSurg and Neurotechnology and Orthopaedics segments, and the significant contribution from its recent acquisition of Inari Medical. The Inari acquisition particularly bolstered the Vascular business within the MedSurg and Neurotechnology segment.

Net earnings and diluted EPS decreased primarily due to a substantial increase in Selling, General, and Administrative (SG&A) expenses. This increase was largely attributable to acquisition-related costs, including a one-time charge of $139 million for Inari employee stock awards that vested upon acquisition, as well as other integration costs and ongoing investments to support growth.

The Inari acquisition was funded through a combination of cash flows and significant debt issuance. In February 2025, Stryker issued approximately $2.98 billion in senior unsecured notes. The company ended the quarter with $2.32 billion in cash and cash equivalents, and a healthy current ratio, indicating strong liquidity to support operations and ongoing strategic initiatives.

The acquisition of Inari Medical is a strategic move to expand Stryker's presence in the minimally invasive treatment of venous thromboembolism. Inari's product portfolio complements Stryker's existing Vascular business within the MedSurg and Neurotechnology segment, offering opportunities for cross-selling, innovation, and further market penetration in a growing area of medical technology.